Please assess the completion status of the following clinical trial:

Trial Title: Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Patients with symptomatic Dry eye~  * Shirmer ≤10 mm in 5 min~ * BUT ≤10 seconds~ * Corneal staining ≥3~ * Age range: 18 years and older.~ * Both genders and all ethnic groups comparable with the local community.~ * Able to understand and willing to sign a written informed consent~ * Able and willing to cooperate with the investigational plan.~ * Able and willing to complete all mandatory follow-up visits.~Exclusion Criteria:~* • Patients who are currently engaged in another clinical trial, unwilling or unable to give consent, to accept randomization, or to return for scheduled visits.~  * Children under 18.~ * Pregnant women or expecting to be pregnant during the study.~ * Systemic immune deficient conditions such as AIDS or under systemic immunosuppressant.~ * Concomitant use of systemic antibiotics or steroids.~ * Contact lens wear~ * Active ocular infection or allergy~ * Unable to close eyes or uncontrolled blinking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Platelet -Rich Plasma (PRP) (Type: EXPERIMENTAL): 15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
- Standard Care (Type: ACTIVE_COMPARATOR): 15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90

Based on this trial design, predict the completion outcome and termination type (if applicable).